Department of Health and Social Sciences, University of West England, Bristol, UK.
Department of Infection Sciences, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
BMJ Open. 2019 May 1;9(4):e024918. doi: 10.1136/bmjopen-2018-024918.
To explore what approaches to patient and public involvement (PPI) in antimicrobial medicines development are currently being used, what the impacts of PPI are on antimicrobial medicines development and what the barriers are to its implementation.
Interview study.
Antimicrobial medicines development research.
Principal investigators known to have led studies involving PPI or expressed an interest in PPI.
There is very little published work on PPI in antimicrobial research. Individual interviewees expressed scepticism about the contribution that PPI could make to different stages of the medicines development life cycle but collectively identified a range of potential benefits of PPI covering most stages of the medicines development process.
A major issue in developing PPI in antimicrobial medicines development research will be in overcoming the view that, at best, PPI has only a marginal contribution to make in this area of research. The findings from this study, although mixed, suggest that well-designed PPI has an untapped potential to enhance antimicrobial research.
探讨目前在抗菌药物开发中采用了哪些患者和公众参与（PPI）方法，PPI 对抗菌药物开发的影响是什么，以及实施 PPI 的障碍是什么。
访谈研究。
抗菌药物开发研究。
已知有主导涉及 PPI 的研究或对 PPI 感兴趣的主要研究者。
关于抗菌研究中的 PPI，发表的相关工作非常少。个别受访者对 PPI 能为药物开发生命周期的不同阶段做出的贡献表示怀疑，但集体确定了 PPI 在药物开发过程的大多数阶段的一系列潜在益处。
在抗菌药物开发研究中开展 PPI 的一个主要问题将是克服这样一种观点，即 PPI 在这一研究领域的贡献充其量只是微不足道的。尽管这项研究的结果喜忧参半，但它表明精心设计的 PPI 具有挖掘增强抗菌研究潜力的未开发潜力。
